Switch to:
Also traded in: Denmark, Germany, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt 90.39
OTCPK:NONOF's Cash-to-Debt is ranked higher than
51% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. OTCPK:NONOF: 90.39 )
Ranked among companies with meaningful Cash-to-Debt only.
OTCPK:NONOF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.29  Med: 1.8 Max: 90.39
Current: 90.39
0.29
90.39
Equity-to-Asset 0.46
OTCPK:NONOF's Equity-to-Asset is ranked lower than
74% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OTCPK:NONOF: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
OTCPK:NONOF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46  Med: 0.63 Max: 0.73
Current: 0.46
0.46
0.73
Interest Coverage 544.18
OTCPK:NONOF's Interest Coverage is ranked lower than
67% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OTCPK:NONOF: 544.18 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:NONOF' s Interest Coverage Range Over the Past 10 Years
Min: 9.18  Med: 279.29 Max: 884.41
Current: 544.18
9.18
884.41
Piotroski F-Score: 5
Altman Z-Score: 11.36
Beneish M-Score: -2.83
WACC vs ROIC
9.33%
143.18%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 43.33
OTCPK:NONOF's Operating Margin % is ranked higher than
95% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. OTCPK:NONOF: 43.33 )
Ranked among companies with meaningful Operating Margin % only.
OTCPK:NONOF' s Operating Margin % Range Over the Past 10 Years
Min: 21.38  Med: 35.7 Max: 45.81
Current: 43.33
21.38
45.81
Net Margin % 33.93
OTCPK:NONOF's Net Margin % is ranked higher than
94% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. OTCPK:NONOF: 33.93 )
Ranked among companies with meaningful Net Margin % only.
OTCPK:NONOF' s Net Margin % Range Over the Past 10 Years
Min: 20.38  Med: 26.62 Max: 33.93
Current: 33.93
20.38
33.93
ROE % 88.84
OTCPK:NONOF's ROE % is ranked higher than
99% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. OTCPK:NONOF: 88.84 )
Ranked among companies with meaningful ROE % only.
OTCPK:NONOF' s ROE % Range Over the Past 10 Years
Min: 27.38  Med: 50.43 Max: 82.23
Current: 88.84
27.38
82.23
ROA % 42.39
OTCPK:NONOF's ROA % is ranked higher than
98% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. OTCPK:NONOF: 42.39 )
Ranked among companies with meaningful ROA % only.
OTCPK:NONOF' s ROA % Range Over the Past 10 Years
Min: 18.46  Med: 30 Max: 41.29
Current: 42.39
18.46
41.29
ROC (Joel Greenblatt) % 174.85
OTCPK:NONOF's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. OTCPK:NONOF: 174.85 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
OTCPK:NONOF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43  Med: 107.33 Max: 178.92
Current: 174.85
43
178.92
3-Year Revenue Growth Rate 12.40
OTCPK:NONOF's 3-Year Revenue Growth Rate is ranked higher than
62% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. OTCPK:NONOF: 12.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
OTCPK:NONOF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -46.3  Med: 12.4 Max: 127.9
Current: 12.4
-46.3
127.9
3-Year EBITDA Growth Rate 15.30
OTCPK:NONOF's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OTCPK:NONOF: 15.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
OTCPK:NONOF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -44.4  Med: 14.7 Max: 130.3
Current: 15.3
-44.4
130.3
3-Year EPS without NRI Growth Rate 17.00
OTCPK:NONOF's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. OTCPK:NONOF: 17.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
OTCPK:NONOF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 16.7 Max: 36.9
Current: 17
1.3
36.9
GuruFocus has detected 1 Warning Sign with Novo Nordisk A/S $OTCPK:NONOF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» OTCPK:NONOF's 10-Y Financials

Financials (Next Earnings Date: 2017-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with OTCPK:NONOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2836
Compare:NAS:CELG, NAS:GILD, NAS:AMGN, NAS:BIIB, OTCPK:SHPGF, OTCPK:CSLLY, NAS:REGN, NAS:VRTX, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, OTCPK:GIKLY, NAS:BMRN, OTCPK:NVZMF, OTCPK:UCBJY, OTCPK:GMXAY, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:TSRO » details
Traded in other countries:NOVO B.Denmark, NOVA.Germany, NOVOB.Switzerland, 0QIU.UK, NVO.USA,
Headquarter Location:Denmark
Novo Nordisk A/S is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company has two business segments: diabetes & obesity care and biopharmaceuticals.

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, as well as oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 20% of revenue) that specializes in protein-related therapies for hemophilia and other disorders.

Ratios

vs
industry
vs
history
PE Ratio 17.77
NONOF's PE Ratio is ranked higher than
75% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. NONOF: 17.77 )
Ranked among companies with meaningful PE Ratio only.
NONOF' s PE Ratio Range Over the Past 10 Years
Min: 12.13  Med: 23.59 Max: 34.41
Current: 17.77
12.13
34.41
Forward PE Ratio 16.98
NONOF's Forward PE Ratio is ranked higher than
58% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. NONOF: 16.98 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.77
NONOF's PE Ratio without NRI is ranked higher than
76% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. NONOF: 17.77 )
Ranked among companies with meaningful PE Ratio without NRI only.
NONOF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.13  Med: 23.58 Max: 34.41
Current: 17.77
12.13
34.41
Price-to-Owner-Earnings 20.39
NONOF's Price-to-Owner-Earnings is ranked higher than
67% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. NONOF: 20.39 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NONOF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.81  Med: 27.38 Max: 59.57
Current: 20.39
13.81
59.57
PB Ratio 14.97
NONOF's PB Ratio is ranked lower than
89% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. NONOF: 14.97 )
Ranked among companies with meaningful PB Ratio only.
NONOF' s PB Ratio Range Over the Past 10 Years
Min: 3.68  Med: 9.23 Max: 31.9
Current: 14.97
3.68
31.9
PS Ratio 6.04
NONOF's PS Ratio is ranked higher than
68% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. NONOF: 6.04 )
Ranked among companies with meaningful PS Ratio only.
NONOF' s PS Ratio Range Over the Past 10 Years
Min: 2.8  Med: 5.83 Max: 11.01
Current: 6.04
2.8
11.01
Price-to-Free-Cash-Flow 16.84
NONOF's Price-to-Free-Cash-Flow is ranked higher than
70% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. NONOF: 16.84 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NONOF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.07  Med: 24.48 Max: 47.08
Current: 16.84
12.07
47.08
Price-to-Operating-Cash-Flow 13.96
NONOF's Price-to-Operating-Cash-Flow is ranked higher than
73% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. NONOF: 13.96 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NONOF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.91  Med: 19.89 Max: 32.54
Current: 13.96
9.91
32.54
EV-to-EBIT 13.72
NONOF's EV-to-EBIT is ranked higher than
65% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. NONOF: 13.72 )
Ranked among companies with meaningful EV-to-EBIT only.
NONOF' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.2  Med: 16.8 Max: 25.7
Current: 13.72
9.2
25.7
EV-to-EBITDA 12.86
NONOF's EV-to-EBITDA is ranked higher than
63% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NONOF: 12.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
NONOF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.2  Med: 16.1 Max: 23.6
Current: 12.86
8.2
23.6
PEG Ratio 1.03
NONOF's PEG Ratio is ranked higher than
75% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. NONOF: 1.03 )
Ranked among companies with meaningful PEG Ratio only.
NONOF' s PEG Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.18 Max: 5.14
Current: 1.03
0.7
5.14
Shiller PE Ratio 32.84
NONOF's Shiller PE Ratio is ranked higher than
75% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. NONOF: 32.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
NONOF' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.12  Med: 42.66 Max: 67.58
Current: 32.84
23.12
67.58
Current Ratio 1.26
NONOF's Current Ratio is ranked lower than
84% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. NONOF: 1.26 )
Ranked among companies with meaningful Current Ratio only.
NONOF' s Current Ratio Range Over the Past 10 Years
Min: 1.26  Med: 2.21 Max: 3.09
Current: 1.26
1.26
3.09
Quick Ratio 0.96
NONOF's Quick Ratio is ranked lower than
85% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NONOF: 0.96 )
Ranked among companies with meaningful Quick Ratio only.
NONOF' s Quick Ratio Range Over the Past 10 Years
Min: 0.96  Med: 1.46 Max: 2.6
Current: 0.96
0.96
2.6
Days Inventory 288.81
NONOF's Days Inventory is ranked lower than
84% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. NONOF: 288.81 )
Ranked among companies with meaningful Days Inventory only.
NONOF' s Days Inventory Range Over the Past 10 Years
Min: 246.45  Med: 282.52 Max: 343.56
Current: 288.81
246.45
343.56
Days Sales Outstanding 66.07
NONOF's Days Sales Outstanding is ranked lower than
54% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. NONOF: 66.07 )
Ranked among companies with meaningful Days Sales Outstanding only.
NONOF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.09  Med: 51.9 Max: 66.07
Current: 66.07
45.09
66.07
Days Payable 127.69
NONOF's Days Payable is ranked higher than
72% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. NONOF: 127.69 )
Ranked among companies with meaningful Days Payable only.
NONOF' s Days Payable Range Over the Past 10 Years
Min: 72.54  Med: 100.02 Max: 127.69
Current: 127.69
72.54
127.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.90
NONOF's Dividend Yield % is ranked higher than
88% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. NONOF: 2.90 )
Ranked among companies with meaningful Dividend Yield % only.
NONOF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.93  Med: 1.57 Max: 4.17
Current: 2.9
0.93
4.17
Dividend Payout Ratio 0.63
NONOF's Dividend Payout Ratio is ranked lower than
84% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. NONOF: 0.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NONOF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.63
Current: 0.63
0.26
0.63
3-Year Dividend Growth Rate 37.70
NONOF's 3-Year Dividend Growth Rate is ranked higher than
89% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. NONOF: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NONOF' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 18.6 Max: 37.7
Current: 37.7
0
37.7
Forward Dividend Yield % 2.90
NONOF's Forward Dividend Yield % is ranked higher than
91% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 1.05 vs. NONOF: 2.90 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 11.58
NONOF's 5-Year Yield-on-Cost % is ranked higher than
95% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. NONOF: 11.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NONOF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.71  Med: 6.27 Max: 16.65
Current: 11.58
3.71
16.65
3-Year Average Share Buyback Ratio 1.80
NONOF's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NONOF: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NONOF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: 0.7 Max: 8
Current: 1.8
-13.6
8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 90.41
NONOF's Price-to-Net-Current-Asset-Value is ranked lower than
98% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. NONOF: 90.41 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
NONOF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 11.62  Med: 24.24 Max: 100.73
Current: 90.41
11.62
100.73
Price-to-Tangible-Book 15.93
NONOF's Price-to-Tangible-Book is ranked lower than
86% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. NONOF: 15.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NONOF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.14  Med: 6.39 Max: 23.2
Current: 15.93
3.14
23.2
Price-to-Intrinsic-Value-Projected-FCF 1.58
NONOF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
77% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. NONOF: 1.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NONOF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 2.5 Max: 7.38
Current: 1.58
1.45
7.38
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.62
NONOF's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
96% of the 24 Companies
in the Global Biotechnology industry.

( Industry Median: 1.21 vs. NONOF: 0.62 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.03
NONOF's Price-to-Median-PS-Value is ranked higher than
55% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NONOF: 1.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NONOF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.86 Max: 1.65
Current: 1.03
0.5
1.65
Price-to-Peter-Lynch-Fair-Value 0.91
NONOF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
83% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NONOF: 0.91 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
NONOF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.27  Med: 1.02 Max: 3.78
Current: 0.91
0.27
3.78
Price-to-Graham-Number 3.55
NONOF's Price-to-Graham-Number is ranked lower than
59% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. NONOF: 3.55 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NONOF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.56  Med: 2.8 Max: 5.52
Current: 3.55
1.56
5.52
Earnings Yield (Greenblatt) % 7.29
NONOF's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. NONOF: 7.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NONOF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.9  Med: 6 Max: 10.8
Current: 7.29
3.9
10.8
Forward Rate of Return (Yacktman) % 23.55
NONOF's Forward Rate of Return (Yacktman) % is ranked higher than
65% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. NONOF: 23.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NONOF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.5  Med: 22.9 Max: 33.5
Current: 23.55
7.5
33.5

More Statistics

Revenue (TTM) (Mil) $16,551
EPS (TTM) $ 2.22
Beta0.90
Short Percentage of Float0.00%
52-Week Range $31.07 - 58.05
Shares Outstanding (Mil)2,550.00

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 16,453 17,614 18,593
EPS ($) 2.24 2.36 2.53
EPS without NRI ($) 2.24 2.36 2.53
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.75%
Dividends per Share ($) 1.23 1.57 1.69
» More Articles for OTCPK:NONOF

Headlines

Articles On GuruFocus.com
Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day Apr 17 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Action Law Mar 08 2017 
NVO Lead Plaintiff Deadline Reminder: Hagens Berman Reminds Novo Nordisk Investors of March 13, 2017 Mar 06 2017 
DEADLINE ALERT: Brower Piven Reminds Investors Of The March 13, 2017 Deadline In Class Action Lawsui Mar 05 2017 
NOVO NORDISK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS Mar 04 2017 
New Features: Individual Portfolio Tracker and Value Screens Tracker Mar 03 2017 
NVO DEADLINE NOTICE: Rosen Law Firm Reminds Novo Nordisk A/S Investors of Important March 13 Deadlin Mar 02 2017 
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
NVO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving No Feb 08 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Novo Nordis Feb 07 2017 

More From Other Websites
Novo Nordisk has been accused of engaging in a 'white coat marketing scheme' to sell diabetes drugs Apr 28 2017
Novo Settles U.S. Probe of Kickbacks, Disguised Salespeople Apr 28 2017
3 Beaten-Up Healthcare Stocks: Are They Bargains? Apr 19 2017
High-Yield Healthcare Investments You Can Buy Right Now Apr 18 2017
5 Pharmaceutical Stocks With the Most Reliable Dividends Apr 09 2017
[$$] The Charms of Bayer and Novo Nordisk Apr 07 2017
Ailing Novo Seeks Cure With Diabetes Drug Targeting Fat Too Apr 06 2017
Novo Nordisk A/S breached its 50 day moving average in a Bullish Manner : NONOF-US : April 3, 2017 Apr 03 2017
Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion Mar 28 2017
Novo Nordisk A/S :NONOF-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
3 Tremendously Promising Diabetes Drugs Potentially on the Way Mar 26 2017
3 Top Diabetes Care Stocks to Buy in 2017 Mar 17 2017
A drug company just struck a deal to discount the price of a lifesaving diabetes medication to $25 Mar 16 2017
Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays Mar 13 2017
Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of... Mar 10 2017
Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors Mar 10 2017
Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk Mar 08 2017
Why Global Blood Therapeutics Rocketed Higher Today Mar 08 2017
Global Blood Therapeutics Stock Surging on Nordisk Bid Speculation Mar 08 2017
Novo Seen Missing Target of 40 Million Diabetics Treated by 2020 Mar 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)